Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

11/11/2021 | 06:31am EST

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15 at 3:20pm ET.

A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.


ę Business Wire 2021
All news about SAGE THERAPEUTICS, INC.
01/10SAGE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
01/06Needham Adjusts Sage Therapeutics Price Target to $85 From $79, Reiterates Buy Rating
MT
01/04Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tu..
BU
2021SVB Leerink Adjusts Sage Therapeutics PT to $60 From $70, Maintains Market Perform Rati..
MT
2021Sage Therapeutics Third Annual FutureCast Showcases Data from All Three Brain Health Fr..
AQ
2021Sage Therapeutics' Third Annual FutureCast Showcases Data from All Three Brain Health F..
BU
2021Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Developm..
AQ
2021Sage Therapeutics, Biogen Report Positive Data From Antidepressant Drug Candidate Zuran..
MT
2021SAGE THERAPEUTICS : and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the On..
PU
2021SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 6,65 M - -
Net income 2021 -458 M - -
Net cash 2021 1 433 M - -
P/E ratio 2021 -4,84x
Yield 2021 -
Capitalization 2 224 M 2 224 M -
EV / Sales 2021 119x
EV / Sales 2022 17,1x
Nbr of Employees 298
Free-Float 87,6%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | SAGE | US78667J1088 | MarketScreener
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 37,75 $
Average target price 73,05 $
Spread / Average Target 93,5%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer & Treasurer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-11.26%2 224
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.95%47 873
BIONTECH SE-37.66%38 812